LIFESCAPES is a researcher and manufacturer of brain-computer interface equipment. LIFESCAPES aims to use BMI technology to help stroke patients solve problems and improve their quality of life. LIFESCAPES uses BMI to bring out the plasticity of the brain and help people who are in trouble to be free of their limitations and to live their lives normally.
K Pharma Is the development Of the Treatment Of the Spinal Cord injury
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Luxonus is a product development of a new imaging device using optical ultrasonic technology.
Grace Imaging specializes in advanced fatigue measurement services that utilize lactate sensing in sweat and MRI technologies. The company has developed a device designed to measure lactic acid concentration in sweat, allowing for precise fatigue analysis. By integrating sweat lactate sensors and MRI techniques, Grace Imaging offers users insights into exercise load and muscle changes, enhancing the understanding of athletic performance and recovery.
Heartseed Inc., founded in 2015 and based in Tokyo, Japan, focuses on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company aims to advance the clinical application of regenerative medicine specifically for treating heart disease. Heartseed is dedicated to creating cardiomyocyte replacement therapies derived from iPS cells to address advanced heart failure, aspiring to transform the treatment landscape for patients suffering from this condition.
AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.
Founded in 2020, Skygate Technologies is building a network to deliver a
large volume of data from observation satellites around the Earth to the
ground and integrating the network into the web architecture. “Make
Space accessible on the Web” is its motto, and the ability to develop both
hardware and software is its strength. More information about Skygate
Technologies can be found at www.skygate-tech.com.
Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus is comprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms.
BONX Inc. plans, designs, and develops wearable devices. The company offers BONX Grip, a Bluetooth earpiece with music, calls, and group-talks snowboarding, cycling, SUP, and fishing sports persons. It sells its products online. The company was founded in 2014 and is based in Tokyo, Japan.
APB Co., Ltd., founded in 2018 and based in Tokyo, Japan, specializes in the research, development, manufacture, and sales of advanced lithium-ion batteries. The company focuses on creating next-generation lithium-ion and all-polymer batteries designed to address existing challenges in battery technology. Through its innovative approach, APB aims to enhance battery performance and reliability, catering to various sectors that require efficient energy storage solutions.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Luxonus is a product development of a new imaging device using optical ultrasonic technology.
Synspective Inc. provides data by utilizing and integrating data from synthetic aperture radar satellite constellations, big data, and machine learning. It serves urban design, infrastructure, energy, insurance, and finance markets. The company is based in Tokyo, Japan.
Motion Lib, Inc. is a Japanese company specializing in haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 in Kawasaki, the company initially operated under the name Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib develops advanced chips that estimate and calculate the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovative technology facilitates the integration of machines into various sectors, thereby expanding their operational capabilities and contributing to overall societal productivity.
Instalimb, Inc. is a Tokyo-based company specializing in the development of low-cost prosthetics through advanced technologies such as 3D computer-aided design, 3D printing, and machine learning. As the world's first business focused on 3D printed prostheses, Instalimb aims to make prosthetic devices more accessible and affordable for individuals in need. The innovative approach combines cutting-edge technology with a commitment to improving the quality of life for users, setting a new standard in the prosthetic industry.
xenodata lab., In the mission "Technology proposal suggests naturally after five years", in order to make the shape of the future financial industry with novel technology, ideas February 2016 It was founded in. xenodata is a coined word that spells the idea of creating heterogeneous creatures according to data, and by means of the intelligence created by the data, the meaning to pursue the substitution of human actions to the utmost is put in the meaning.
Luxonus is a product development of a new imaging device using optical ultrasonic technology.
Himuka AM Pharma is a pharmaceutical company based in Miyazaki City, Japan, founded in February 2017. The company focuses on the research, development, and discovery of new drug seeds aimed at enhancing adrenomedullin, a peptide involved in various physiological processes. Through its innovative approach, Himuka AM Pharma seeks to contribute to advancements in medical treatments and improve health outcomes.
CureApp is a digital health startup.The firm is one of the leading players in the medical app vertical under the theme of “app exhibits therapeutic effects against diseases” and launched a nicotine addiction treatment app in February 2015, which was jointly developed with Division of Pulmonary Medicine, Keio University’s School of Medicine. It is currently conducting clinical trials in many locations.
BONX Inc. plans, designs, and develops wearable devices. The company offers BONX Grip, a Bluetooth earpiece with music, calls, and group-talks snowboarding, cycling, SUP, and fishing sports persons. It sells its products online. The company was founded in 2014 and is based in Tokyo, Japan.
Tsubota Laboratory, Inc. is a Tokyo-based company established in 2015 that focuses on research and development aimed at treating dry eye symptoms. The company specializes in creating dietary supplements designed to alleviate the discomfort associated with dry eye, myopia, and presbyopia. Through its innovative approach, Tsubota Laboratory seeks to provide effective solutions for individuals suffering from these conditions.
Institution for a Global Society is a a French graduate school with students from 70 countries around the world
IDAC Theranostics, Inc. engages in research, development, and production of pharmaceutical products for the treatment of cancer, graft-versus-host disease (GVHD), inflammation diseases, diagnostics, and other diseases. The company was founded in 2012 and is based in Tokyo, Japan.
Motion Lib, Inc. is a Japanese company specializing in haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 in Kawasaki, the company initially operated under the name Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib develops advanced chips that estimate and calculate the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovative technology facilitates the integration of machines into various sectors, thereby expanding their operational capabilities and contributing to overall societal productivity.
Generic Solution Corporation provides software distribution services. The company also provides data analytics and artificial intelligence services. Generic Solution Corporation was founded in 2006 and is based in Tokyo, Japan.
BONX Inc. plans, designs, and develops wearable devices. The company offers BONX Grip, a Bluetooth earpiece with music, calls, and group-talks snowboarding, cycling, SUP, and fishing sports persons. It sells its products online. The company was founded in 2014 and is based in Tokyo, Japan.
CureApp is a digital health startup.The firm is one of the leading players in the medical app vertical under the theme of “app exhibits therapeutic effects against diseases” and launched a nicotine addiction treatment app in February 2015, which was jointly developed with Division of Pulmonary Medicine, Keio University’s School of Medicine. It is currently conducting clinical trials in many locations.
AdipoSeeds, though a novel technology, creates platelets from mesenchymal stem cells without a complex and costly gene transfer. It aims to invent new blood supply system to solve the shortage of platelets in the world, and to create a future where a platelet-related treatment will be cheaply and safely provided.
Quan Inc. develops content for smartphone applications and web. The company develops characters contents such as Betakkuma, Sugar Cubs, Business Fish, Piyomaru, sticker shop for au Smartpass, Mr.Egg, Elice, Kawaii Kaomoji Book, handwritten stickers, AIS MystickerShop and game contents that includes emotipon. The company offers characters for mobile carriers, chatting applications and platforms of Japan and Southeast Asian nations. Quan Inc. was founded in 2011 and is based in Tokyo, Japan.
Kringle Pharma, Inc. is a biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF) protein medicines and NK4 molecules. Established in 2001 and headquartered in Japan, the company aims to harness the regenerative properties of HGF for various medical conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scarring. In addition to HGF, Kringle Pharma develops NK4, which acts as an antagonist to HGF and exhibits anti-cancer properties by inhibiting tumor cell invasion and metastasis. The company's product pipeline includes recombinant human HGF for treating acute renal failure, skin ulcers, and central nervous system disorders, as well as NK4 and NK4 gene therapies for cancer treatment.
SENSY Inc. is a Tokyo-based company founded in November 2011 that focuses on personal artificial intelligence designed to enhance user experiences by understanding individual sensitivities. The company offers business-to-consumer and business-to-business services, as well as support for launching new business-related offerings. By leveraging its AI technology, SENSY aims to create meaningful and transformative interactions that cater to the diverse lifestyles of its users.